-- 周二，日本股市收低，此前日本央行维持政策利率在0.75%不变，并指出经济前景存在更大的不确定性。 日经225指数下跌1.02%，或619.90点，收于59,917.46点。 三位理事反对这一决定，他们呼吁加息，这加剧了市场对政策可能转变的预期。日本央行行长上田一夫表示，由于中东冲突带来的不确定性，实现央行预测的可能性有所降低。 他指出，风险呈现双向波动，经济增长面临下行压力，而通胀面临上行风险，尤其是在2026财年，这使得评估经济和物价波动的持续时间和影响变得困难。 其他经济新闻方面，日本3月份失业率从2.6%升至2.7%，就业人数降至6815万人，失业人数增至186万人。 企业方面，电装（TYO:6902）股价下跌约3%，此前该公司撤回了收购罗姆（TYO:6963）股份的提议，理由是缺乏支持且价值上涨空间有限。 日产汽车（TYO:7201）股价上涨约4%，此前该公司预测2025财年亏损将收窄，预计每股亏损157.42日元，净亏损5500亿日元，同时销售额略有增长。 出光兴产（TYO:5019）股价上涨约3%，此前有报道称，该公司将通过绕过霍尔木兹海峡的航线向越南供应约400万桶原油。
Related Articles
International
U.S. Energy Production Climbs 3% YoY in January, EIA Reports
U.S. primary energy production rose 3% year over year in January to 9.1 quadrillion British thermal units, the U.S. Energy Information Administration said in its Monthly Energy Review released Monday.Total fossil fuels production in January was made up of 46% dry natural gas, 31% crude oil, 12% crude oil and 11% natural gas plant liquids, the EIA reported.Total renewable energy production was composed of 56% biomass, 20% wind, 12% hydroelectric power, 11% solar and 1% geothermal energy, according to the agency.U.S. natural gas plant liquids production was 7% higher in January than in the year-ago month. Dry natural gas production and renewable energy production each climbed 4%. Nuclear electric power production and coal production each increased 2%. Crude oil production rose 1%.
$CLX1$LCOX1$NGV1$UNG$UNL$USO
Asia
CanSino Biologics Widens Loss in Q1
CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.
$HKG:6185$SHA:688185
Japan